The malignant pleural effusion market is projected to grow from USD 5.1 billion in 2025 to USD 9.1 billion by 2035, at a CAGR of 6.0%. Pleural Fluid Cytology will dominate with a 29.3% market share, while hospitals will lead the end user segment with a 66.1% share.